Protein kinase C zeta promotes thyroid Cancer progression and represents a novel therapeutic target: evidence from specific atypical PKC inhibitor 2-acetyl-1,3-cyclopentanedione inhibitor studies.

ABSTRACT:

Background

Poorly differentiated and anaplastic thyroid carcinomas represent aggressive malignancies with limited therapeutic options and poor prognosis. Protein kinase C zeta (PKCζ), an atypical PKC isozyme, has emerged as a critical regulator in various cancers, but its role in thyroid cancer progression remains largely unexplored. This study investigated PKCζ expression patterns in thyroid cancer and evaluated its therapeutic potential using the specific atypical PKC inhibitor 2-acetyl-1,3-cyclopentanedione (ACPD).

Methods

PKCζ expression and phosphorylation were analyzed in thyroid tissue samples from 20 patients and multiple thyroid cancer cell lines using Western blot analysis. Functional studies employed PKCζ overexpression, knockdown, and ACPD treatment in BCPAP (pap

SUBMITTER: Ding J 

PROVIDER: S-EPMC12835205 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature